Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma

SIMPLE SUMMARY: FGFR4 is a receptor tyrosine kinase overexpressed in rhabdomyosarcoma (RMS) and mutationally activated in ~10% of fusion-negative (FN) cases. The goal of this study was to evaluate the preclinical efficacy of futibatinib, a novel FGFR-family inhibitor, in treating RMS. We demonstrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jerry T., Cheuk, Adam, Isanogle, Kristine, Robinson, Christina, Zhang, Xiaohu, Ceribelli, Michele, Beck, Erin, Shinn, Paul, Klumpp-Thomas, Carleen, Wilson, Kelli M., McKnight, Crystal, Itkin, Zina, Sotome, Hiroshi, Hirai, Hiroshi, Calleja, Elizabeth, Wacheck, Volker, Gouker, Brad, Peer, Cody J., Corvalan, Natalia, Milewski, David, Kim, Yong Y., Figg, William D., Edmondson, Elijah F., Thomas, Craig J., Difilippantonio, Simone, Wei, Jun S., Khan, Javed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452847/
https://www.ncbi.nlm.nih.gov/pubmed/37627061
http://dx.doi.org/10.3390/cancers15164034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452847/
https://www.ncbi.nlm.nih.gov/pubmed/37627061
http://dx.doi.org/10.3390/cancers15164034

Ejemplares similares